STM2457 Transferase Inhibition Targets METTL3 to Reverse Doxorubicin Resistance in Osteosarcoma

Schematic diagram of METTL3 m6A RNA methylation pathway inhibition restoring doxorubicin sensitivity in osteosarcoma
Feel free to reference this image, but please provide a link back.
Copy code to add this image to your page

Acquired resistance to standard chemotherapeutic agents, particularly anthracyclines such as doxorubicin, remains a major clinical obstacle in the management of high-grade osteosarcoma. Emerging evidence indicates that epitranscriptomic modifications, predominantly N6-methyladenosine (m6A) RNA methylation, govern critical transcript fates that mediate drug tolerance, cell survival, and metastatic spread. Methyltransferase-like 3 (METTL3) serves as the primary S-adenosylmethionine (SAM)-dependent catalytic subunit of the intracellular m6A writer complex. In resistant osteosarcoma states, METTL3 expression is frequently upregulated, driving aberrant m6A deposition across key oncogenic transcripts. Pharmacological engagement of the METTL3 active site using the small-molecule inhibitor STM2457 offers a direct method to modulate this epitranscriptomic axis.

Biochemical evaluations demonstrate that the STM2457 Transferase inhibitor binds competitively within the SAM-binding pocket of METTL3. This binding event selectively blocks SAM cofactor binding without altering the secondary structure of adjacent regulatory subunits such as METTL14. In osteosarcoma models, transcriptomic and m6A sequencing identified melanoma cell adhesion molecule (MCAM) mRNA as a high-affinity target of METTL3 activity. Increased m6A deposition within the 3' untranslated region of MCAM transcripts recruits specific m6A reader proteins, which stabilizes the transcript and enhances translation. High cellular levels of MCAM protein subsequently drive aggressive focal adhesion kinetics, cell proliferation, and active efflux mechanisms that compromise doxorubicin efficacy.

To overcome systemic toxicity and poor physiological stability of free small molecules, researchers developed biomimetic nanoparticles loaded with STM2457 (SM@STM2457-NPs). These nanocarriers incorporate osteosarcoma cell membrane coatings modified with the tumor-penetrating peptide iRGD. The biomimetic outer shell promotes homologous targeting to primary and metastatic osteosarcoma lesions, while the iRGD ligand facilitates deep tissue penetration through binding to alpha-v integrins and neuropilin-1. Intracellular release of STM2457 systematically disrupts METTL3 catalytic activity, triggering rapid hypomethylation of MCAM mRNA transcripts.

In vitro functional assays using doxorubicin-resistant osteosarcoma cell lines confirm that treatment with SM@STM2457-NPs markedly attenuates cell proliferation, colony formation, migration, and invasive capacity. Western blot and quantitative RT-PCR analyses verify a corresponding drop in both m6A modification levels and total MCAM protein expression following treatment. When administered in combination with doxorubicin, SM@STM2457-NPs restore chemotherapeutic sensitivity, lowering IC50 values to levels comparable with parental, non-resistant osteosarcoma cell lines.

In vivo validation was performed using orthotopic osteosarcoma xenografts and tail-vein pulmonary metastasis murine models. Systemic administration of SM@STM2457-NPs combined with doxorubicin resulted in pronounced tumor volume reduction and significantly decreased the number of pulmonary metastatic nodules compared to mono-chemotherapy groups. Histopathological analysis of major organs demonstrated negligible off-target toxicity, confirming the biocompatibility of the biomimetic nanocarrier system. These empirical observations establish targeting of METTL3-mediated m6A MCAM methylation as a viable approach to overcome chemotherapy resistance in osteosarcoma.


Biomimetic Nanotherapy Reverses Epitranscriptomic Chemotherapy Resistance

STM2457 target pathway diagram of METTL3 m6A RNA methylation signaling pathway during osteosarcoma chemosensitization
Feel free to reference this image, but please provide a link back.
Copy code to add this image to your page

STM2457 selectively inhibits METTL3 methyltransferase activity within the SAM-binding domain, suppressing m6A RNA modification of MCAM transcripts in osteosarcoma cells. Formulated into iRGD-modified biomimetic nanoparticles (SM@STM2457-NPs), this targeted delivery system downregulates MCAM protein expression. Reduced MCAM expression impairs cancer cell proliferation, invasion, and metastatic dissemination. In xenograft and metastatic mouse models, combining SM@STM2457-NPs with doxorubicin attenuates chemoresistance and restricts tumor progression, establishing an epitranscriptomic intervention strategy for resistant osteosarcoma.

Biomimetic Nanoparticles Enhance STM2457 Delivery to Osteosarcoma

Targeted drug delivery to dense osteosarcoma stroma poses significant pharmacological challenges. To bypass rapid clearance, researchers synthesized biomimetic nanoparticles encapsulating the STM2457 Transferase inhibitor. The outer shell incorporates osteosarcoma cell membrane fractions combined with surface iRGD peptide motifs. This dual-functional coating directs nanoparticles to primary and secondary tumor sites. In cellular uptake assays, internal fluorescence intensity peaked within four hours. Active targeting increased drug uptake fourfold over non-functionalized carriers. The nanoparticle core provides sustained drug release under physiological conditions; catalytic suppression of METTL3 persisted for over 48 hours post-administration. Within tested murine xenografts, accumulation at the tumor site remained elevated, minimizing off-target exposure in cardiac and renal tissues.

Downregulation of MCAM Methylation Suppresses Metastasis and Proliferation

Mechanistic analysis confirmed that METTL3 directly methylates specific adenosine sites within MCAM mRNA. Pharmacological inhibition by STM2457 reduced m6A enrichment on MCAM transcripts by more than 60%. Consequently, transcript decay accelerated, leading to reduced MCAM protein synthesis. Lowered MCAM levels altered focal adhesion dynamics and suppressed cell motility. In vitro invasion through Matrigel matrix declined significantly following treatment. Short anchoring sentences highlight these phenotypic shifts plain textually. Cellular proliferation slowed within 24 hours; combining SM@STM2457-NPs with doxorubicin reactivated cleavage of PARP and caspase-3. In pulmonary metastasis mouse models, combination therapy reduced metastatic nodule counts by 78% compared to doxorubicin alone.


References

[1]. Song D, et al. Journal of Translational Medicine. 2025;23(1).

Resources